SGMT logo

SGMT Sagimet Biosciences Inc.

NASDAQ · Biotechnology · Healthcare

$9.08
-0.54 (-5.61%)

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunc…

Market Cap: $648.02Mwww.sagimet.com

Price

No data yet.

Social Signal Score

55
5d
—
30d
50
1 mentions
—
60d
57
10 mentions
—
90d
58
12 mentions
—
news: 12

Analyst Ratings

9 analysts
Buyconsensus
Strong Buy 0Buy 8Hold 1Sell 0Strong Sell 0
Avg price target$21.4+135.7%
Low $7Median $26High $29
Current Consensus

Revenue

$0.00
$0.00$666.7K$1.33M$2.00M
Mar 2022Sep 2026

Analyst Estimates

FY2025
$-1.66
$-1.69–$-1.62
7 analysts
FY2026
$-1.21
$-1.46–$-1.13
8 analysts
FY2027
$-1.44
$-1.89–$-1.28
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
David Happel
Sector
Healthcare
Industry
Biotechnology
Employees
16
Beta
3.47
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
8.01
www.sagimet.com